-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA grants accelerated approval to J&J's Rybrevant Faspro for advanced head and neck cancer

PUBT·11/06/2026 02:04:27
Listen to the news
FDA grants accelerated approval to J&J's Rybrevant Faspro for advanced head and neck cancer
  • Johnson & Johnson secured FDA accelerated approval for Rybrevant Faspro as a single-agent treatment for recurrent or metastatic head and neck cancer.
  • Eligible adults must have progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody; HPV-associated oropharyngeal cancer is excluded.
  • The pivotal trial showed a 42% overall response rate. Continued approval may depend on confirmatory clinical benefit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611052103PR_NEWS_USPR_____AQ90862) on November 06, 2026, and is solely responsible for the information contained therein.